Zacks Research Has Pessimistic Outlook of PCRX Q4 Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Analysts at Zacks Research decreased their Q4 2024 earnings per share estimates for shares of Pacira BioSciences in a research report issued on Wednesday, November 27th. Zacks Research analyst R. Department now expects that the company will earn $0.58 per share for the quarter, down from their previous forecast of $0.62. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.28 per share.

A number of other brokerages have also recently issued reports on PCRX. JPMorgan Chase & Co. reissued an “underweight” rating and issued a $10.00 target price (down from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. HC Wainwright decreased their target price on Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Piper Sandler cut Pacira BioSciences from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $42.00 to $11.00 in a research report on Monday, August 12th. Royal Bank of Canada upped their target price on Pacira BioSciences from $15.00 to $16.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. Finally, Truist Financial cut Pacira BioSciences from a “buy” rating to a “sell” rating and decreased their target price for the company from $30.00 to $8.00 in a research report on Tuesday, August 13th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Pacira BioSciences currently has an average rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Trading Down 6.3 %

PCRX opened at $16.68 on Monday. Pacira BioSciences has a one year low of $11.16 and a one year high of $35.95. The company has a market cap of $770.12 million, a P/E ratio of -8.22 and a beta of 0.80. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The business’s 50-day simple moving average is $16.58 and its 200-day simple moving average is $19.57.

Institutional Trading of Pacira BioSciences

Several hedge funds have recently modified their holdings of the business. GAMMA Investing LLC increased its position in Pacira BioSciences by 229.6% during the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after buying an additional 932 shares in the last quarter. Park Place Capital Corp acquired a new position in shares of Pacira BioSciences during the second quarter worth about $46,000. Innealta Capital LLC purchased a new stake in shares of Pacira BioSciences during the second quarter worth about $50,000. nVerses Capital LLC increased its position in shares of Pacira BioSciences by 800.0% during the second quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock worth $51,000 after acquiring an additional 1,600 shares during the last quarter. Finally, CWM LLC increased its holdings in Pacira BioSciences by 713.6% in the third quarter. CWM LLC now owns 6,517 shares of the company’s stock valued at $98,000 after buying an additional 5,716 shares during the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.